Related Experiment Video
Updated: Mar 31, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization
Sebastian Kuger1, Michael Flentje2, Cholpon S Djuzenova2
1Department of Radiation Oncology, University Hospital of Würzburg, Würzburg, Germany. melanie.gardeur@biomedcentral.com.
Background:
The mitogen-activated protein kinases (MAPK) and the phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways are intertwined on various levels and simultaneous inhibition reduces tumorsize and prolonges survival synergistically. Furthermore, inhibiting these pathways radiosensitized cancer cells in various studies. To assess, if phenotypic changes after perturbations of this signaling network depend on the genetic background, we integrated a time series of the signaling data with phenotypic data after simultaneous MAPK/ERK kinase (MEK) and PI3K/mTOR inhibition and ionizing radiation (IR).
Methods:
The MEK inhibitor AZD6244 and the dual PI3K/mTOR inhibitor NVP-BEZ235 were tested in glioblastoma and lung carcinoma cells, which differ in their mutational status in the MAPK and the PI3K/mTOR pathways. Effects of AZD6244 and NVP-BEZ235 on the proliferation were assessed using an ATP assay. Drug treatment and IR effects on the signaling network were analyzed in a time-dependent manner along with measurements of phenotypic changes in the colony forming ability, apoptosis, autophagy or cell cycle.
Results:
Both inhibitors reduced the tumor cell proliferation in a dose-dependent manner, with NVP-BEZ235 revealing the higher anti-proliferative potential. Our Western blot data indicated that AZD6244 and NVP-BEZ235 perturbed the MAPK and PI3K/mTOR signaling cascades, respectively. Additionally, we confirmed crosstalks and feedback loops in the pathways. As shown by colony forming assay, the AZD6244 moderately radiosensitized cancer cells, whereas NVP-BEZ235 caused a stronger radiosensitization. Combining both drugs did not enhance the NVP-BEZ235-mediated radiosensitization. Both inhibitors caused a cell cycle arrest in the G1-phase, whereas concomitant IR and treatment with the inhibitors resulted in cell line- and drug-specific cell cycle alterations. Furthermore, combining both inhibitors synergistically enhanced a G1-phase arrest in sham-irradiated glioblastoma cells and induced apoptosis and autophagy in both cell lines.
Conclusion:
Perturbations of the MEK and the PI3K pathway radiosensitized tumor cells of different origins and the combination of AZD6244 and NVP-BEZ235 yielded cytostatic effects in several tumor entities. However, this is the first study assessing, if the combination of both drugs also results in synergistic effects in terms of radiosensitivity. Our study demonstrates that simultaneous treatment with both pathway inhibitors does not lead to synergistic radiosensitization but causes cell line-specific effects.
Insights
Simultaneous inhibition of MAPK/ERK kinase (MEK) and PI3K/mammalian target of rapamycin (mTOR) pathways radiosensitizes cancer cells, but combining MEK and PI3K/mTOR inhibitors does not enhance this effect. The drug combination shows cell line-specific cytostatic effects rather than synergistic radiosensitization.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Mitogen-activated protein kinases (MAPK) and phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways are crucial in cancer.
- Simultaneous inhibition of these pathways can synergistically reduce tumor size and prolong survival.
- Previous studies show that inhibiting these pathways can radiosensitize cancer cells.
Purpose of the Study:
- To investigate if phenotypic changes after perturbing the MAPK/ERK kinase (MEK) and PI3K/mTOR signaling network depend on the genetic background.
- To assess the effects of simultaneous MEK and PI3K/mTOR inhibition combined with ionizing radiation (IR) on cancer cells.
- To determine if combining MEK and PI3K/mTOR inhibitors leads to synergistic radiosensitization.
Main Methods:
- Glioblastoma and lung carcinoma cells with differing mutational statuses were treated with MEK inhibitor AZD6244 and dual PI3K/mTOR inhibitor NVP-BEZ235.
- Cell proliferation was measured using an ATP assay.
- Signaling pathway perturbations, colony formation, apoptosis, autophagy, and cell cycle changes were analyzed over time following drug treatment and/or IR.
Main Results:
- Both AZD6244 and NVP-BEZ235 reduced tumor cell proliferation dose-dependently, with NVP-BEZ235 being more potent.
- AZD6244 moderately radiosensitized cancer cells, while NVP-BEZ235 showed stronger radiosensitization; combining them did not enhance this effect.
- The drug combination induced synergistic G1-phase arrest, apoptosis, and autophagy in a cell line- and drug-specific manner, but not synergistic radiosensitization.
Conclusions:
- Perturbing MEK and PI3K pathways radiosensitizes tumor cells, and the combination of AZD6244 and NVP-BEZ235 exhibits cytostatic effects.
- Simultaneous treatment with AZD6244 and NVP-BEZ235 does not result in synergistic radiosensitization.
- The combination therapy demonstrates cell line-specific effects on cancer cell phenotypes, including cell cycle arrest, apoptosis, and autophagy.
Related Concept Videos
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway

